The first study the ARETTA Study (Assessing response to neoadjuvant Taxotere and Trastuzumab in Nigerian women with HER2-positive breast cancer (ClinicalTrials.gov Identifier: NCT03879577) is now being conducted at the four centers in Nigeria under the sponsorship and close supervision of the University of Chicago USA. Here, ERBB2 is linked to breast cancer.